Acadia Pharmaceuticals, Inc. (ACAD) Posts Q1 Loss of 12c/Share
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $27.29 -0.58%
EPS Growth %: -52.4%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -52.4%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q1 EPS of ($0.12), $0.01 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $450 thousand versus the consensus estimate of $500 thousand.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
- Redburn upgrades Southwest, stays bullish on Delta and United
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
